Studies focusing on the tumor microenvironment have revealed that fatostatin decreases SREBP2 activation and intracellular cholesterol accumulation, leading to a reduction in regulatory T (Treg) cells—immunosuppressive cells—while alleviating CD8+ T cell exhaustion in the TME (Zhu et al., 2024). Here, SREBF2 is linked to neoplasm.